Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Shareholder Alert: Robbins LLP Announces That Bluebird Bio, Inc. (BLUE) is Being Sued for Misleading Shareholders
06:41pm, Wednesday, 17'th Feb 2021
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of bluebird bio, Inc. (NASDAQ: BLUE) filed a class action compl
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
04:35pm, Wednesday, 17'th Feb 2021
BENSALEM, Pa.--(BUSINESS WIRE)---- $BLUE #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of Investors
bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies
12:08pm, Wednesday, 17'th Feb 2021
bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.
New York, New York--(Newsfile Corp. - February 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities
Why bluebird bio Stock Is Plunging Today
01:13pm, Tuesday, 16'th Feb 2021
The company had to halt one of its clinical studies following a suspected severe adverse reaction.
Bluebird Bio Temporarily Suspends Sickle Cell Gene Therapy Studies Following Incidences of Blood Cancer
11:13am, Tuesday, 16'th Feb 2021
Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. What Happened: Cambridge, Massachusetts-based Bluebird said it has placed t
Bluebird Stock Collapses To 7-Year Low On Safety Concern In Gene Therapy
09:38am, Tuesday, 16'th Feb 2021
Bluebird Bio temporarily suspended all studies of a sickle cell disease gene therapy on Tuesday — prompting BLUE stock to collapse. Shares hit a seven-year low in early trading.
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #BLUE--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc.
Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment
07:37am, Tuesday, 16'th Feb 2021
Shares of Bluebird Bio Inc. slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell diseas
Atlanta, Georgia--(Newsfile Corp. - February 16, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) an
New York, New York--(Newsfile Corp. - February 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #BLUE--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc.
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of bluebird bio, Inc. (NASDA
NEW YORK--(BUSINESS WIRE)-- #bluebirdbio--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States Di
